Clidinium bromide

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Clidinium 是一种合成抗胆碱能化合物，实验和临床研究表明其对胃肠道具有显着的解痉和抗分泌作用。

Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. (In Vivo):Clidinium (oral gavage; 0.25, 0.5, and 1 mg/kg; 3 days) causes constipation in mice. It leads to a significant decrease in %transit after clidinium treatment [(F(3, 28)=27.405] in mice.Clidinium (oral gavage; 0.25, 0.5, and 1 mg/kg; 3 days) has a significant effect on the clonic seizure threshold induced by intravenous PTZ which received clidinium (0.25, 0.5, and 1 mg/kg) [(F(3, 35) = 14.103].

——

Clidinium (oral gavage; 0.25, 0.5, and 1 mg/kg; 3 days) causes constipation in mice. It leads to a significant decrease in %transit after clidinium treatment [(F(3, 28)=27.405] in mice.Clidinium (oral gavage; 0.25, 0.5, and 1 mg/kg; 3 days) has a significant effect on the clonic seizure threshold induced by intravenous PTZ which received clidinium (0.25, 0.5, and 1 mg/kg) [(F(3, 35) = 14.103]. Animal Model:Male NMRI mice weighing 20-25 g Dosage:0.25, 0.5, and 1 mg/kg Administration:Oral gavage; 0.25, 0.5, and 1 mg/kg; 3 days Result:Decreased the clonic seizure latency compared with control animals.

Ro 2-3773

Endocrinology/Hormones

AChR

mAChR

Neurological Disease

——

3485-62-9

432.35

C22H26BrNO3

>98% (HPLC)

DMSO: 10 mM

C[N+]12CCC(CC1)C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O.[Br-]

(1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl) 2-hydroxy-2,2-diphenylacetate;bromide

(-20℃)

With Ice Pack

≥ 2 years